Profile data is unavailable for this security.
About the company
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
- Revenue in USD (TTM)1.31m
- Net income in USD-597.65m
- Incorporated2014
- Employees622.00
- LocationImmunitybio Inc3530 JOHN HOPKINS COURTSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 633-0300
- Fax+1 (302) 674-5266
- Websitehttps://immunitybio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 493.67m | -104.69m | 3.19bn | 517.00 | -- | 17.86 | -- | 6.47 | -0.3461 | -0.3461 | 1.63 | 0.5987 | 0.6367 | 0.5739 | 5.76 | 954,876.20 | -13.50 | -30.65 | -17.12 | -36.55 | 89.99 | 88.94 | -21.21 | -86.10 | 2.42 | 0.3214 | 0.6853 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Iovance Biotherapeutics Inc | 90.86m | -410.00m | 3.23bn | 557.00 | -- | 4.19 | -- | 35.58 | -1.50 | -1.50 | 0.3273 | 2.54 | 0.0986 | 3.24 | -- | 163,120.30 | -44.48 | -51.47 | -50.17 | -57.56 | 14.75 | -- | -451.25 | -137,873.80 | 3.90 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Edgewise Therapeutics Inc | 0.00 | -124.29m | 3.31bn | 108.00 | -- | 6.82 | -- | -- | -1.49 | -1.49 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -30.22 | -- | -31.57 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -199.06m | 3.34bn | 251.00 | -- | 3.95 | -- | -- | -2.74 | -2.74 | 0.00 | 11.15 | 0.00 | -- | -- | 0.00 | -25.38 | -20.71 | -26.37 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Kymera Therapeutics Inc | 87.56m | -167.47m | 3.36bn | 184.00 | -- | 3.76 | -- | 38.34 | -2.33 | -2.33 | 1.26 | 13.79 | 0.1103 | -- | 34.37 | 468,251.30 | -21.10 | -23.03 | -22.98 | -27.64 | -- | -- | -191.26 | -207.82 | -- | -- | 0.0035 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| MoonLake Immunotherapeutics | 0.00 | -80.77m | 3.44bn | 50.00 | -- | 6.96 | -- | -- | -1.29 | -1.29 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -16.25 | -- | -18.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 32.87m | 727.43m | 3.45bn | 383.00 | 4.92 | 2.12 | 4.70 | 104.90 | 12.28 | 11.37 | 0.5778 | 28.53 | 0.0235 | 0.1598 | 15.31 | 85,825.06 | 51.98 | -29.54 | 55.50 | -31.88 | 89.38 | -- | 2,212.98 | -3,826.10 | 8.77 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Apogee Therapeutics Inc | 0.00 | -118.49m | 3.54bn | 91.00 | -- | 4.43 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Alvotech SA | 308.73m | -618.38m | 3.68bn | 999.00 | -- | -- | -- | 11.92 | -2.65 | -2.65 | 1.28 | -2.27 | 0.312 | 1.80 | 3.66 | 309,038.00 | -62.49 | -- | -222.85 | -- | 48.79 | -- | -200.30 | -- | 0.1569 | -0.2323 | 2.04 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Immunitybio Inc | 1.31m | -597.65m | 3.80bn | 622.00 | -- | -- | -- | 2,902.22 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Rhythm Pharmaceuticals Inc | 112.53m | -261.57m | 4.03bn | 226.00 | -- | 359.25 | -- | 35.82 | -4.31 | -4.31 | 1.86 | 2.49 | 0.3136 | 1.18 | 6.65 | 497,920.30 | -72.15 | -47.21 | -90.85 | -52.84 | 88.61 | -- | -230.11 | -681.38 | 3.34 | -- | 0.417 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Denali Therapeutics Inc | 0.00 | -427.49m | 4.55bn | 390.00 | -- | 3.45 | -- | -- | -2.76 | -2.76 | 0.00 | 9.17 | 0.00 | -- | -- | 0.00 | -31.77 | -14.98 | -33.76 | -17.71 | -- | -- | -- | -104.50 | -- | -- | 0.0043 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Immunovant Inc | 0.00 | -323.01m | 4.56bn | 207.00 | -- | 10.16 | -- | -- | -2.21 | -2.21 | 0.00 | 3.06 | 0.00 | -- | -- | 0.00 | -79.97 | -- | -92.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Immunitybio Inc's reporting currency: US Dollar USD
6.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 13.46m | 1.93% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 9.85m | 1.41% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 7.86m | 1.13% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.92m | 0.56% |
| Jane Street Capital LLCas of 30 Jun 2024 | 1.72m | 0.25% |
| MultiConcept Fund Management SAas of 30 Jun 2024 | 1.30m | 0.19% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 1.24m | 0.18% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 1.14m | 0.16% |
| JPMorgan Asset Management (UK) Ltd.as of 30 Sep 2024 | 947.22k | 0.14% |
| First Trust Advisors LPas of 30 Jun 2024 | 887.62k | 0.13% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
